Qubigen CEO Dr. Jonathan Hall to Speak at SBEI25 on Federated AI for Global Health & Drug Design
- David Brooks
- Oct 13
- 2 min read
Qubigen is pleased to share that its CEO, Dr. Jonathan Hall, will be a featured speaker at the upcoming Society for Bioinformatics and Computational Biology (SBEI) Conference, where he will discuss Federated AI for Global Health & Drug Design. SBEI25 is hosted by ABACBS (the Australian Bioinformatics and Computational Biology Society) and explores the transformative role of generative AI and its real-world application across health, biotechnology, science and agriculture, bringing together leading researchers, technologists, and industry innovators from around the world.
Date | Monday, 24 November 2025 |
Time | 10:10 AM |
Location | Adelaide Oval, War Memorial Dr, North Adelaide SA 5006 |
Session | 1 - Rethinking the Toolbox: AI that reimagines, creates and transforms |
As an invited speaker, Dr. Hall will discuss how Qubigen’s innovative, privacy-preserving technology is accelerating drug design, allowing collaboration between institutions. He will explore how Qubigen’s patented Federated AI platform securely leverages global data to deliver AI Engines, without moving or seeing the data. Qubigen’s curated database and tailored transformer-like AI engines can make cognitive leaps in the generation of optimized, highly novel compounds for first-in-class potential, even for tough undruggable targets.
Qubigen is actively seeking collaborators, clients, and partnerships with organizations interested in leveraging Federated AI for drug design. Qubigen invites conference attendees to connect with Dr. Hall during the event to discuss opportunities.
Qubigen: accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
